We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Mar 2022
  • Code : CMI4960
  • Pages : 167
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
Ingographics Image

Gonadotropin-releasing hormone (GnRH) agonist are potential treatment options for the CPP as they inhibit stimulation effects of endogenous GnRH and accelerate bone maturation, thereby suppressing early puberty. GnRH therapy delays the onset of puberty leading to delay in menarche Triptodor (triptorelin), Lupron Depot-Ped (leuprolide acetate), and Supprelin LA (histrelin acetate) are approved treatment medications available in the market for central precocious puberty (CPP). Moreover, Triptodur, Lupron Depot-Ped, and Supprelin LA are Gonadotropin-releasing hormone (GnRH) agonists used to prolong the suppression of gonadotropin secretion when required. Triptorelin, a GnRH agonist, effectively suppresses the pituitary-gonadal axis and pubertal development in children with CPP.

Market Dynamics

Reimbursement for the treatment of central precocious puberty is provided through Medicaid, which is expected to offer lucrative growth opportunities for the global central precocious puberty market during the forecast period. According to N.C. Medicaid Bulletin December 2017, Triptodur: an extended-release injectable suspension for intramuscular use, operates under Medicaid Healthcare Common Procedure Coding System (HCPCS) code J3490. According to the same source, from September 2017, N.C. Medicaid and N.C. Health Choice (NCHC) programs cover triptorelin extended-release injectable suspension for intramuscular use (Triptodur) for use in the Physician's Drug Program (PDP). For Medicaid and NCHC billing, the maximum reimbursement rate per unit of Triptodur is: US$ 17,280.00 per kit.

Key features of the study:

  • This report provides an in-depth analysis of the global central precocious puberty market, market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global central precocious puberty market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie Inc., Arbor Pharmaceuticals, LLC, Pfizer Inc., Tolmar Pharmaceuticals, Inc., Endo International plc, Ipsen Pharma, Debiopharm Group, and Sun Pharmaceutical Industries Limited
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global central precocious puberty market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global central precocious puberty market

Detailed Segmentation:

  • Global Central Precocious Puberty Market, By Drug:
    • Leuprolide Acetate
    • Triptorelin
    • Histrelin Acetate
    • Nafarelin
  • Global Central Precocious Puberty Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Central Precocious Puberty Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • AbbVie Inc.
    • Arbor Pharmaceuticals, LLC
    • Pfizer Inc.
    • Tolmar Pharmaceuticals, Inc.
    • Endo International plc
    • Ipsen Pharma
    • Debiopharm Group
    • Sun Pharmaceutical Industries Limited

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Industry Trends
    • Pricing Analysis
    • Regulatory Scenario
    • Recent Product Approvals/Launches
    • PEST Analysis
  4. Global Central Precocious Puberty Market - Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Epidemiology
    • Impact on Demand and Supply
    • Impact on overall Healthcare Sector
  5. Global Central Precocious Puberty Market, By Drug, 2017-2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 - 2030
      • Segment Trends
    • Leuprolide Acetate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
    • Triptorelin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
    • Histrelin Acetate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
    • Nafarelin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  6. Global Central Precocious Puberty Market, By Distribution Channel, 2017 - 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 - 2030
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
  7. Global Central Precocious Puberty Market, By Region, 2017 - 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018 - 2030
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2017 - 2030 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Company Profiles
      • Teva Pharmaceutical Industries Ltd.*
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • AbbVie Inc.
      • Arbor Pharmaceuticals, LLC.
      • Pfizer Inc.
      • Tolmar Pharmaceuticals, Inc.
      • Endo Pharmaceuticals Inc.
      • Ipsen Pharma
      • Debiopharm Group
      • Sun Pharmaceutical Industries Limited

*Key pointers provided are also applicable to other companies covered in the scope of the report.

  1. Section
    • Research Methodology
    • About Us
    • Contact

*Browse 33 market data tables and 25 figures on "Central Precocious Puberty Market” - Global Forecast to 2030.

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
  • Want to Buy a Report but have a Limited Budget?

    We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

    Request Discount
Logo

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo